Psoriatic Arthritis Market Landscape: 6 Key Late-Stage Drugs Set to Drive Future Growth | DelveInsight

The psoriatic arthritis market is expected to expand significantly through 2036 driven by emerging late-stage therapies from major pharmaceutical companies. Key drugs in development include tildrakizumab (Sun Pharma), sonelokimab (MoonLake), icotrokinra (Johnson & Johnson), zasocitinib (Takeda), izokibep (Affibody Medical), and vunakizumab (Suzhou Suncadia). These novel biologic and oral small-molecule therapies aim to address unmet needs among patients with inadequate responses to existing treatments.

09/21/2026, 1:00 PM • GlobeNewswire

Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape

The global autoimmune disease therapeutics market is projected to grow from USD 132.75 billion in 2025 to USD 254.60 billion by 2034, at a CAGR of 7.5%. Growth is driven by rising autoimmune disease diagnoses, increased adoption of biologics and targeted oral therapies, biosimilar expansion, and emerging cell and gene therapies. Biologics dominate with 66% market share, TNF inhibitors lead drug classes at 29%, and rheumatoid arthritis accounts for 34% of revenue. North America holds 44% regional share while Asia-Pacific is expected to grow fastest.

09/17/2026, 6:49 AM • GlobeNewswire

Palmoplantar Pustulosis Market Report Now Available — Profiles AbbVie, Johnson & Johnson, Novartis, Amgen, UCB, and 4 Other Key Players, Segmented by Treatment Type and Distribution Channel

The global palmoplantar pustulosis market is experiencing steady growth driven by increased awareness, diagnosis rates, and development of targeted biologic therapies. Key advances in IL-23 and IL-36 research, precision medicine, and AI-assisted diagnostics are accelerating treatment development. While topical therapies remain central for mild cases, systemic agents and biologics are supporting moderate-to-severe disease management. Growth is reinforced by clinical trials and regulatory approvals across North America, Europe, and Asia-Pacific, though high treatment costs and limited access in developing regions remain challenges.

08/31/2026, 5:03 AM • GlobeNewswire

Financière de Tubize - Rapport financier semestriel 2026

La Financière de Tubize a publié son rapport financier semestriel 2026 montrant un bénéfice de €100,8 millions (+5,4% YoY). La société a perçu €102,3 millions de dividendes d'UCB (+4,3%) et a versé €48,1 millions de dividendes à ses actionnaires (+3,8%). Elle a acquis 15.783 titres UCB pour €4,05 millions, portant sa participation à 36,29%.

08/07/2026, 7:40 AM • GlobeNewswire

Financière de Tubize - 2026 half-year financial report

Financière de Tubize reported a profit of €100.8 million for the first half of 2026, up 5.4% year-over-year. The company received €102.3 million in dividends from UCB (up 4.3%) and paid shareholders €48.1 million in dividends (up 3.8%). Financière de Tubize increased its stake in UCB to 36.29% by acquiring 15,783 shares for €4.05 million.

08/07/2026, 7:40 AM • GlobeNewswire

Financière de Tubize - Halfjaarlijks verslag 2026

Financière de Tubize reported H1 2026 results with net profit of €100.8 million (up 5.4% YoY) and received €102.3 million in dividends from UCB. The company distributed €48.1 million in dividends to shareholders (up 3.8% YoY) and acquired 15,783 UCB shares, increasing its stake to 36.29%.

08/07/2026, 7:40 AM • GlobeNewswire

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

Over 25 pharmaceutical companies are advancing 30+ pipeline drugs for myasthenia gravis treatment, with approximately 5+ therapies in late-stage development. Key players including Immunovant, Cartesian Therapeutics, Novartis, and others are developing promising therapies using novel mechanisms of action such as IgG degraders and complement inhibitors. Recent developments include positive Phase III trial results and regulatory approvals for multiple candidates.

06/02/2026, 1:00 PM • GlobeNewswire

Myasthenia Gravis Market Set to Surpass USD 16 Billion by 2036, Fueled by Rising Diagnosed Prevalence and Wave of Targeted Biologic Approvals | DelveInsight

The myasthenia gravis market is projected to grow from USD 6 billion in 2025 to over USD 16 billion by 2036, driven by rising diagnosed prevalence, improved diagnostics, and an expanding pipeline of targeted biologic therapies including FcRn inhibitors, complement inhibitors, and CAR-T cell therapies. The market is currently led by argenx and UCB, with numerous emerging candidates in late-stage development expected to significantly accelerate growth.

05/18/2026, 1:00 PM • GlobeNewswire

Crohn's Disease Eight-Market Drug Forecast and Market Analysis Report 2025-2026: Novel MOAs Will Provide Market Shifts Throughout the Forecast Period to 2032

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

04/10/2026, 4:43 AM • GlobeNewswire

UCB - Convocation à l'assemblée générale des actionnaires 2026

UCB SA convenes its General Shareholders Meeting for April 30, 2026, to approve 2025 annual accounts, a dividend of €1.45 per share, and renew mandates for CEO Jean-Christophe Tellier and administrator Cédric van Rijckevorsel. The meeting will also address capital authorization renewal, share buyback authorization up to 10%, and approval of EMTN program change-of-control clauses.

03/27/2026, 2:00 AM • GlobeNewswire

UCB - Convening Notice to the General Meeting of the Shareholders 2026

UCB SA/NV has issued a convening notice for its General Meeting of Shareholders scheduled for April 30, 2026, in Brussels. The agenda includes approval of 2025 annual accounts with a proposed dividend of €1.45 per share, renewal of director mandates for Jean-Christophe Tellier (CEO) and Cédric van Rijckevorsel, and authorization renewals for the Board of Directors regarding authorized capital and share buybacks. The meeting will also address approval of change of control provisions in the EMTN Program.

03/27/2026, 2:00 AM • GlobeNewswire

UCB - Oproeping tot de algemene vergadering van aandeelhouders 2026

UCB NV announces its General Shareholders Meeting scheduled for April 30, 2026, covering routine matters including approval of 2025 financial statements, dividend distribution of €1.45 per share, renewal of board mandates for CEO Jean-Christophe Tellier and director Cédric van Rijckevorsel, and approval of control change clauses in the EMTN program. The extraordinary session will address renewal of board authorization for capital increases and share buyback programs.

03/27/2026, 2:00 AM • GlobeNewswire

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Johnson & Johnson announced positive Phase 2b results for nipocalimab, an experimental FcRn blocker for treating systemic lupus erythematosus (SLE). The JASMINE study of 228 subjects met its primary endpoint and key secondary endpoints, with a favorable safety profile. The company plans to initiate Phase 3 trials. The lupus treatment market includes competing programs from UCB/Biogen, Cartesian Therapeutics, and Adicet Bio.

01/06/2026, 1:42 PM • Benzinga

MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th

A class action lawsuit has been filed against MoonLake Immunotherapeutics alleging misleading investors about its drug candidate sonelokimab, which failed to demonstrate superiority in Phase 3 trials, causing the stock to plummet 89.9%.

12/13/2025, 9:21 AM • GlobeNewswire

MOONLAKE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm

A class action lawsuit has been filed against MoonLake Immunotherapeutics alleging misleading investors about its drug candidate sonelokimab, which failed to demonstrate superiority in Phase 3 trials, causing the stock to plummet by nearly 90%.

12/10/2025, 6:14 PM • GlobeNewswire